Free Trial
NASDAQ:CRTX

Cortexyme (CRTX) Stock Price, News & Analysis

Cortexyme logo
$0.99 -0.01 (-0.95%)
As of 04/17/2025

About Cortexyme Stock (NASDAQ:CRTX)

Key Stats

Today's Range
$0.98
$1.13
50-Day Range
$0.99
$1.54
52-Week Range
$1.78
$40.66
Volume
107,724 shs
Average Volume
620,672 shs
Market Capitalization
$29.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Stock News Headlines

Crism Thera Regulatory News
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Headlines

CRTX Stock Analysis - Frequently Asked Questions

Cortexyme's stock was trading at $1.85 on January 1st, 2025. Since then, CRTX shares have decreased by 46.5% and is now trading at $0.9905.
View the best growth stocks for 2025 here
.

Cortexyme, Inc. (NASDAQ:CRTX) released its quarterly earnings data on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.05.

Cortexyme (CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T).

Company Calendar

Last Earnings
8/09/2021
Today
4/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:CRTX
Fax
N/A
Employees
55
Year Founded
2012

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
0.25

Miscellaneous

Free Float
21,739,000
Market Cap
$29.86 million
Optionable
Not Optionable
Beta
1.40

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CRTX) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners